GSK plc (NYSE:GSK) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its position in GSK plc (NYSE:GSK) by 167.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 18,773 shares of the pharmaceutical company’s stock after purchasing an additional 11,749 shares during the period. SG Americas Securities LLC’s holdings in GSK were worth $767,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Register Financial Advisors LLC bought a new position in GSK in the 1st quarter worth $31,000. Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK during the second quarter worth approximately $37,000. Richardson Financial Services Inc. acquired a new position in shares of GSK during the fourth quarter worth approximately $40,000. PrairieView Partners LLC bought a new stake in shares of GSK during the second quarter worth approximately $47,000. Finally, Triad Wealth Partners LLC bought a new stake in shares of GSK during the second quarter worth approximately $49,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Down 1.0 %

NYSE:GSK opened at $38.83 on Friday. The firm’s fifty day moving average is $41.50 and its 200-day moving average is $41.38. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. GSK plc has a 52 week low of $33.67 and a 52 week high of $45.92. The firm has a market cap of $80.47 billion, a P/E ratio of 14.07, a P/E/G ratio of 1.30 and a beta of 0.65.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The company had revenue of $9.95 billion for the quarter, compared to analyst estimates of $9.49 billion. Equities analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were paid a $0.3843 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date of this dividend was Friday, August 16th. GSK’s dividend payout ratio is currently 55.80%.

Insider Activity

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The shares were bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the purchase, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 10.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on GSK. Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. UBS Group lowered shares of GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Barclays upgraded shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research report on Thursday, June 20th. Finally, Argus raised shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.